AstraZeneca: lung cancer drug trial fails; shares hit
(CercleFinance.com) - AstraZeneca's cancer drug Imfinzi has failed in a late-stage trial in patients with stage IV (metastatic) non-small cell lung cancer, hurting the Anglo-Swedish drugmaker's shares on Friday.
The company said that the phase III study showed Imfinzi monotherapy and the combination of Imfinzi plus Pfizer's tremelimumab did not meet the primary endpoint of improving overall survival compared to chemotherapy.
While AstraZeneca said it was "disappointed" by the results, the group plans to continue to assess the drug's potential in ongoing non-small cell lung cancer trials.
Imfinzi is also being tested in a range of other trials, including bladder cancer, head and neck cancer and other solid tumours.
AstraZeneca shares are down over 3.1% at around 6,123 pence after this announcement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The company said that the phase III study showed Imfinzi monotherapy and the combination of Imfinzi plus Pfizer's tremelimumab did not meet the primary endpoint of improving overall survival compared to chemotherapy.
While AstraZeneca said it was "disappointed" by the results, the group plans to continue to assess the drug's potential in ongoing non-small cell lung cancer trials.
Imfinzi is also being tested in a range of other trials, including bladder cancer, head and neck cancer and other solid tumours.
AstraZeneca shares are down over 3.1% at around 6,123 pence after this announcement.
Copyright (c) 2018 CercleFinance.com. All rights reserved.